Study #2023-0538
A phase II study Bolstering outcomes by optimizing immunotherapy strategies with evolocumab and nivolumab in patients with metastatic renal cell carcinoma (BOOST-RCC)
MD Anderson Study Status
Not Accepting
Treatment Agent
Evolocumab, Nivolumab
Description
To learn if evolocumab and nivolumab can control metastatic and refractory renal cell carcinoma. The safety of this drug combination will also be studied.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Metastatic Renal Cell Carcinoma
Study phase:
Phase II
Physician name:
Eric Jonasch
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-844-263-9133
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.